Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp (ADPT) priced its initial public offering on Jun 27, 2019 at $20.00 per share, above its $18.00–$19.00 range, raising $300M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.42B. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan, TD Cowen and Guggenheim and others. DLA Piper advised the company and Fenwick & West advised the underwriters.

Adaptive Biotechnologies Corp is an immune medicine company that uses a proprietary platform to read the genetic code of a patient's adaptive immune system. It uses this clinical immunomics database to develop diagnostic and therapeutic products and services, and has two commercial products and services.

Status

IPO

Ticker

ADPT

Exchange

Nasdaq Global Select

Priced

Jun 27, 2019

IPO price

$20.00

Price range

$18.00–$19.00

Raised

$300M

Market cap at IPO price

$2.42B

First filed

May 30, 2019

Underwriters

Goldman Sachs, J.P. Morgan, TD Cowen, Guggenheim, William Blair and BTIG

Company counsel

DLA Piper

Underwriters' counsel

Fenwick & West

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.